findmyKOL
Clinical trialNCT01639911CompletedPhase 1Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

SponsorUniversity of Illinois at ChicagoEnrollment28CNS MalignancyGenitourinary Neoplasms Malignancy and Gender UnspecifiedHead and Neck NeoplasmsMalignant Neoplasm of BreastMalignant Neoplasm of Gastrointestinal TractMalignant Neoplasm of Thorax+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Illinois Cancer Center

    Chicago, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Aug 2013
Primary completion
28 Jul 2016
Completion
28 Jul 2016
Last update posted
22 Jul 2019
Registered enrollment
28
Registry id
NCT01639911
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.